CCR2

CCR2 is a CC chemokine receptor that mediates MCP-1/CCL2-dependent monocyte chemotaxis, receptor binding, and ligand internalization in inflammatory and vascular contexts^[1][2]. Mechanistically, the CCR2 amino-terminal domain is necessary and sufficient for high-affinity MCP-1 binding, while tyrosine sulfation enhances CCR2 interaction with monomeric and dimeric MCP-1 and supports leukocyte recruitment^[1][3]. In human monocytes, LDL increases CCR2 expression and strengthens MCP-1 chemotactic responses, linking CCR2 signaling to monocyte recruitment during atherogenesis^[4]. In disease models, leukocyte-derived CCR2 is critical for angiotensin II-accelerated atherosclerosis and aneurysm formation in hypercholesterolemic mice^[5]. CCR2 also mediates MCP-1 binding and internalization along brain microvessels, supporting its use in blood-brain barrier and neuroinflammation models^[6]. Compared with related isoforms, CCR2A and CCR2B show cell-specific distribution in idiopathic inflammatory myopathies, where CCR2A appears in vessel walls and mononuclear cells, while CCR2B appears in satellite cells, neuromuscular junction domains, and regenerative fibers^[7]. For experimental applications, MCP-1 binds and activates CCR2B as a monomer, and CCR2-blocking antibodies reduce myeloma-cell migration toward bone marrow stromal chemokines^[8][9].